First Quadrant’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

First Quadrant’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-613	Closed	-$34K	–	694
2019 Q2	$34K	Buy	+613	New	+$32K	﹤0.01%	658

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

First Quadrant's EGRX Position: Q3 2019 in Review

First Quadrant sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2019, closing a stake of 613 shares — an estimated $34K sold.

First Quadrant first reported a position in EGRX in Q2 2019 and held it in 1 quarter. The position peaked at $34K in Q2 2019. 183 funds tracked by Wall St. Rank hold EGRX as of Q3 2019.

First Quadrant reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
First Quadrant sold 613 Eagle Pharmaceuticals, Inc. shares in Q3 2019, an estimated $34K.
First Quadrant first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2019 and held it in 1 quarter.
First Quadrant's Eagle Pharmaceuticals, Inc. position peaked at $34K in Q2 2019.
183 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2019.

Based on First Quadrant's 13F filing for Q3 2019, filed 25 Oct 2019.